ELITE PHARMACEUTICALS INC /NV/ Quarterly Net Income (Loss) Attributable to Parent in USD from Q2 2010 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Elite Pharmaceuticals Inc /Nv/ quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q2 2010 to Q3 2024.
  • Elite Pharmaceuticals Inc /Nv/ Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$11M, a 174% decline year-over-year.
  • Elite Pharmaceuticals Inc /Nv/ Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$6.39M, a 136% decline year-over-year.
  • Elite Pharmaceuticals Inc /Nv/ annual Net Income (Loss) Attributable to Parent for 2023 was $20.1M, a 465% increase from 2022.
  • Elite Pharmaceuticals Inc /Nv/ annual Net Income (Loss) Attributable to Parent for 2022 was $3.56M, a 60% decline from 2021.
  • Elite Pharmaceuticals Inc /Nv/ annual Net Income (Loss) Attributable to Parent for 2021 was $8.9M, a 74.9% increase from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$6.39M -$11M -$26M -174% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-14
Q2 2024 $19.6M $616K -$526K -46.1% Apr 1, 2024 Jun 30, 2024 10-Q 2024-11-14
Q1 2024 $20.1M $3.33M +$4.56M Jan 1, 2024 Mar 31, 2024 10-K 2024-07-01
Q4 2023 $15.6M $706K -$2.26M -76.2% Oct 1, 2023 Dec 31, 2023 10-Q 2024-02-14
Q3 2023 $17.8M $14.9M +$13.4M +886% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-14
Q2 2023 $4.4M $1.14M +$836K +273% Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-14
Q1 2023 $3.56M -$1.23M -$3.66M -151% Jan 1, 2023 Mar 31, 2023 10-K 2024-07-01
Q4 2022 $7.22M $2.97M +$687K +30.1% Oct 1, 2022 Dec 31, 2022 10-Q 2024-02-14
Q3 2022 $6.53M $1.52M -$282K -15.7% Jul 1, 2022 Sep 30, 2022 10-Q 2024-02-14
Q2 2022 $6.82M $306K -$2.08M -87.2% Apr 1, 2022 Jun 30, 2022 10-Q 2024-02-14
Q1 2022 $8.9M $2.43M +$2.91M Jan 1, 2022 Mar 31, 2022 10-K 2023-06-29
Q4 2021 $5.99M $2.28M +$271K +13.5% Oct 1, 2021 Dec 31, 2021 10-Q 2023-02-14
Q3 2021 $5.72M $1.8M -$685K -27.6% Jul 1, 2021 Sep 30, 2021 10-Q 2023-02-14
Q2 2021 $6.4M $2.39M +$1.31M +122% Apr 1, 2021 Jun 30, 2021 10-Q 2023-02-14
Q1 2021 $5.09M -$483K -$1.42M -152% Jan 1, 2021 Mar 31, 2021 10-K 2022-06-29
Q4 2020 $6.51M $2.01M +$3.87M Oct 1, 2020 Dec 31, 2020 10-Q 2022-02-14
Q3 2020 $2.63M $2.48M +$4.08M Jul 1, 2020 Sep 30, 2020 10-Q 2022-02-14
Q2 2020 -$1.44M $1.08M +$798K +285% Apr 1, 2020 Jun 30, 2020 10-Q 2022-02-14
Q1 2020 -$2.24M $936K +$3.6M Jan 1, 2020 Mar 31, 2020 10-K 2021-06-14
Q4 2019 -$5.84M -$1.86M +$484K +20.6% Oct 1, 2019 Dec 31, 2019 10-Q 2021-02-16
Q3 2019 -$6.32M -$1.6M +$988K +38.2% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-16
Q2 2019 -$7.31M $280K +$1.97M Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-14
Q1 2019 -$9.28M -$2.66M +$165K +5.84% Jan 1, 2019 Mar 31, 2019 10-K 2020-06-30
Q4 2018 -$9.44M -$2.34M -$1.85M -378% Oct 1, 2018 Dec 31, 2018 10-Q 2020-02-10
Q3 2018 -$7.59M -$2.58M -$4.4M -242% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-12
Q2 2018 -$3.19M -$1.69M +$481K +22.2% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-09
Q1 2018 -$3.67M -$2.83M +$357K +11.2% Jan 1, 2018 Mar 31, 2018 10-K 2018-06-14
Q4 2017 -$4.03M -$490K -$2.16M -129% Oct 1, 2017 Dec 31, 2017 10-K 2018-06-14
Q3 2017 -$1.87M $1.82M -$2.42M -57.2% Jul 1, 2017 Sep 30, 2017 10-K 2018-06-14
Q2 2017 $550K -$2.17M -$3.27M -297% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-09
Q1 2017 $3.82M -$3.19M -$11.7M -137% Jan 1, 2017 Mar 31, 2017 10-K 2018-06-14
Q4 2016 $15.5M $1.67M +$13.9M Oct 1, 2016 Dec 31, 2016 10-K 2018-06-14
Q3 2016 $1.6M $4.24M +$5.92M Jul 1, 2016 Sep 30, 2016 10-K 2018-06-14
Q2 2016 -$4.32M $1.1M -$3.63M -76.8% Apr 1, 2016 Jun 30, 2016 10-K 2018-06-14
Q1 2016 -$683K $8.5M +$14.8M Jan 1, 2016 Mar 31, 2016 10-K 2018-06-14
Q4 2015 -$15.5M -$12.2M -$19.7M -265% Oct 1, 2015 Dec 31, 2015 10-K 2018-06-14
Q3 2015 $4.12M -$1.68M -$7.93M -127% Jul 1, 2015 Sep 30, 2015 10-K 2018-06-14
Q2 2015 $12M $4.73M +$6.83M Apr 1, 2015 Jun 30, 2015 10-K 2018-06-14
Q1 2015 $5.22M -$6.35M +$80.4M +92.7% Jan 1, 2015 Mar 31, 2015 10-K 2017-06-14
Q4 2014 -$75.2M $7.42M +$8.48M Oct 1, 2014 Dec 31, 2014 10-K 2017-06-14
Q3 2014 -$83.7M $6.25M +$15.9M Jul 1, 2014 Sep 30, 2014 10-K 2017-06-14
Q2 2014 -$99.6M -$2.09M -$3.02M -327% Apr 1, 2014 Jun 30, 2014 10-K 2017-06-14
Q1 2014 -$96.6M -$86.8M -$88.4M -5535% Jan 1, 2014 Mar 31, 2014 10-K 2016-06-15
Q4 2013 -$8.18M -$1.06M -$10.4M -111% Oct 1, 2013 Dec 31, 2013 10-K 2016-06-15
Q3 2013 $2.24M -$9.64M -$10.7M -1018% Jul 1, 2013 Sep 30, 2013 10-K 2016-06-15
Q2 2013 $12.9M $922K +$11.4M Apr 1, 2013 Jun 30, 2013 10-K 2016-06-15
Q1 2013 $1.49M $1.6M +$8.6M Jan 1, 2013 Mar 31, 2013 10-K 2014-06-30
Q4 2012 -$7.11M $9.36M +$602K +6.87% Oct 1, 2012 Dec 31, 2012 10-Q 2014-02-14
Q3 2012 -$7.72M $1.05M -$12.9M -92.5% Jul 1, 2012 Sep 30, 2012 10-Q 2013-11-14
Q2 2012 $5.15M -$10.5M +$20.2M +65.8% Apr 1, 2012 Jun 30, 2012 10-Q 2013-08-14
Q1 2012 -$15.1M -$7.01M +$9.6M +57.8% Jan 1, 2012 Mar 31, 2012 10-K 2013-06-21
Q4 2011 -$24.7M $8.76M +$2.83M +47.8% Oct 1, 2011 Dec 31, 2011 10-Q 2013-02-14
Q3 2011 -$27.5M $13.9M +$12.1M +647% Jul 1, 2011 Sep 30, 2011 10-Q 2012-11-14
Q2 2011 -$39.5M -$30.7M -$26M -544% Apr 1, 2011 Jun 30, 2011 10-Q 2012-08-14
Q1 2011 -$13.6M -$16.6M Jan 1, 2011 Mar 31, 2011 10-K 2012-06-29
Q4 2010 $5.93M Oct 1, 2010 Dec 31, 2010 10-Q 2012-02-14
Q3 2010 $1.86M Jul 1, 2010 Sep 30, 2010 10-Q 2011-11-14
Q2 2010 -$4.77M Apr 1, 2010 Jun 30, 2010 10-Q/A 2011-08-19
* An asterisk sign (*) next to the value indicates that the value is likely invalid.